N-Substituted (2,3-Dihydro-1,4-benzodioxin-2-yl)methylamine Derivatives as D2 Antagonists/5-HT1A Partial Agonists with Potential as Atypical Antipsychotic Agents
- 1 August 1999
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 42 (17) , 3342-3355
- https://doi.org/10.1021/jm9910122
Abstract
A series of N-substituted 1-(2,3-dihydro-1, 4-benzodioxin-2-yl)methylamine derivatives with D(2) antagonist/5-HT(1A) partial agonist activity has been prepared as potential atypical antipsychotic agents. Optimization of in vitro receptor binding activity and in vivo activity in rodent models of psychosis has led to compound 24, which showed good affinities for human D(2), D(3), and 5-HT(1A) receptors but significantly less affinity for human alpha(1) adrenoceptors and rat H(1) and muscarinic receptors. In rodents, 24 showed functional D(2)-like antagonism and 5-HT(1A) partial agonism. After oral dosing, 24 showed good activity in rodent antipsychotic tests and very little potential to cause extrapyramidal side effects (EPS), as measured by its ability to induce catalepsy in rats only at very high doses. In the light of this promising profile of activity, 24 has been selected for clinical investigation as a novel antipsychotic agent with a predicted low propensity to cause EPS.Keywords
This publication has 18 references indexed in Scilit:
- 2-Aminotetralin-derived substituted benzamides with mixed dopamine D2, D3, and serotonin 5-HT1A receptor binding properties: A novel class of potential atypical antipsychotic agentsBioorganic & Medicinal Chemistry, 1998
- Developments in antipsychotic drugs – an updateExpert Opinion on Investigational Drugs, 1998
- Olanzapine (Zyprexa):charactirestics of a new antipsychoticExpert Opinion on Investigational Drugs, 1997
- Schizophrenia - advances in drug therapyExpert Opinion on Investigational Drugs, 1997
- Drug Treatment of Schizophrenia in the 1990sDrugs, 1997
- Incremental dosage of the new antipsychotic mazapertine induces tolerance to cardiovascular and cognitive effects in healthy men*Clinical Pharmacology & Therapeutics, 1996
- Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor bindingPsychopharmacology, 1996
- Pharmacological profile of (−)HT-9OB, a novel 5-HT1A receptor agonist/5-HT2 receptor antagonistProgress in Neuro-Psychopharmacology and Biological Psychiatry, 1995
- Novel Benzodioxan Derivative, 5-{3-[((2S)-1,4-Benzodioxan-2-ylmethyl)amino]propoxy}-l,3-benzodioxole HC1 (MKC-242), with a Highly Potent and Selective Agonist Activity at Rat Central Serotonin1A ReceptorsThe Japanese Journal of Pharmacology, 1995
- Graphics computer-aided receptor mapping as a predictive tool for drug design: development of potent, selective, and stereospecific ligands for the 5-HT1A receptorJournal of Medicinal Chemistry, 1988